TXMD - TherapeuticsMD, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.7800
+0.0400 (+1.46%)
At close: 4:00PM EDT

2.8800 +0.10 (3.60%)
After hours: 7:53PM EDT

Stock chart is not supported by your current browser
Previous Close2.7400
Open2.9000
Bid2.7700 x 4000
Ask2.8000 x 21500
Day's Range2.6650 - 2.8800
52 Week Range1.8200 - 6.9400
Volume2,658,770
Avg. Volume3,604,398
Market Cap670.597M
Beta (3Y Monthly)2.23
PE Ratio (TTM)N/A
EPS (TTM)-0.7150
Earnings DateNov 1, 2017 - Nov 6, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.33
Trade prices are not sourced from all markets
  • Implied Volatility Surging for TherapeuticsMD (TXMD) Stock Options
    Zacks

    Implied Volatility Surging for TherapeuticsMD (TXMD) Stock Options

    Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.

  • Analysts Expect Breakeven For TherapeuticsMD, Inc. (NASDAQ:TXMD)
    Simply Wall St.

    Analysts Expect Breakeven For TherapeuticsMD, Inc. (NASDAQ:TXMD)

    TherapeuticsMD, Inc.'s (NASDAQ:TXMD): TherapeuticsMD, Inc. operates as a women’s health care product company in the...

  • American City Business Journals

    TherapeuticsMD agrees to pay $200,000 to settle SEC charges

    The U.S. Securities and Exchange Commission sued the company for selectively sharing information with analysts that the regulator alleges was not revealed to the public.

  • GuruFocus.com

    Therapeuticsmd Inc (TXMD) CEO Robert G Finizio Bought $95,900 of Shares

    CEO of Therapeuticsmd Inc (30-Year Financial, Insider Trades) Robert G Finizio (insider trades) bought 35,000 shares of TXMD on 08/20/2019 at an average price of $2.74 a share. Continue reading...

  • MarketWatch

    TherapeuticsMD stock slides 6% after SEC charges company with breaking disclosure rules

    TherapeuticsMD Inc. shares slid about 6% Tuesday, after the Securities and Exchange Commission charged the company with breaching Regulation FD, or fair disclosure, for sharing material, non-public information with sell-side research analysts that was not disseminated more widely. The SEC found that on two separate occasions in 2017, TherapeuticsMD selectively shared material information with analysts about its interactions with the Food and Drug Administration. In the first instance, the company on June 15, 2017, a day after a meeting with the FDA about a new drug approval, shared private messages with sell-side analysts in which it described the meeting as "very positive and productive." The stock rallied 19.4% in heavy volume the following day, even though the company had not issued a press release or made a public disclosure about the meeting. On July 17 of the same year, the company issued a press release saying it had submitted additional information to the regulator but did not yet have a clear path toward approval. The stock fell 16% premarket. The SEC then found that in a call and email to sell-side analysts, the company shared further details of its initial FDA meeting, which analysts then included in research notes that helped the stock rebound to close the regular session down just 6.6%. "Information about a pharmaceutical company's interactions with the FDA can be critical to investors," said Carolyn Welshhans, associate director of the SEC's division of enforcement. "It is essential that when companies disseminate material, nonpublic information, they do so fairly and appropriately to all investors and not just a select few analysts." TherapeuticsMD consented to the SEC charge and agreed to pay a $200,000 penalty without admitting or denying the findings. The stock has fallen 31% in 2019, while the S&P 500 has gained 16%.

  • GuruFocus.com

    Therapeuticsmd Inc (TXMD) CEO Robert G Finizio Bought $155,119 of Shares

    CEO of Therapeuticsmd Inc (30-Year Financial, Insider Trades) Robert G Finizio (insider trades) bought 52,405 shares of TXMD on 08/09/2019 at an average price of $2.96 a share. Continue reading...

  • Thomson Reuters StreetEvents

    Edited Transcript of TXMD earnings conference call or presentation 6-Aug-19 8:30pm GMT

    Q2 2019 TherapeuticsMD Inc Earnings Call

  • Here's Why TherapeuticsMD Stock Is Jumping Today
    Motley Fool

    Here's Why TherapeuticsMD Stock Is Jumping Today

    Investors are cheering second-quarter results that were better than expected, and an improved outlook for the year.

  • TherapeuticsMD Inc (TXMD) Q2 2019 Earnings Call Transcript
    Motley Fool

    TherapeuticsMD Inc (TXMD) Q2 2019 Earnings Call Transcript

    TXMD earnings call for the period ending June 30, 2019.

  • TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates

    TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -5.56% and 19.27%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    TherapeuticsMD Announces Second Quarter 2019 Financial Results

    IMVEXXY® Net Revenue $3.1 Million for the Second Quarter of 2019

  • Business Wire

    TherapeuticsMD to Report Second Quarter 2019 Results on August 6, 2019

    TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that it will report its second quarter 2019 financial results on Tuesday, August 6, 2019, after the closing of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 4:30 p.m. ET on such date to discuss the Company’s financial results and provide a business update. A live webcast and audio archive for the event may be accessed on the home page or from the “Investors & Media” section of the TherapeuticsMD website at www.therapeuticsmd.com.

  • Earnings Preview: TherapeuticsMD (TXMD) Q2 Earnings Expected to Decline
    Zacks

    Earnings Preview: TherapeuticsMD (TXMD) Q2 Earnings Expected to Decline

    TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Before You Buy TherapeuticsMD, Inc. (NASDAQ:TXMD), Consider Its Volatility
    Simply Wall St.

    Before You Buy TherapeuticsMD, Inc. (NASDAQ:TXMD), Consider Its Volatility

    If you own shares in TherapeuticsMD, Inc. (NASDAQ:TXMD) then it's worth thinking about how it contributes to the...

  • Thomson Reuters StreetEvents

    Edited Transcript of TXMD earnings conference call or presentation 6-May-19 8:30pm GMT

    Q1 2019 TherapeuticsMD Inc Earnings Call

  • Benzinga

    Jim Cramer Shares His Thoughts On TherapeuticsMD, Rite Aid And More

    On CNBC's "Mad Money Lightning Round,"  Jim Cramer said he likes Yeti Holdings Inc (NYSE: YETI ) very much. He believes the stock is undervalued and he sees it as a long-time hold. Daktronics, ...

  • Markit

    See what the IHS Markit Score report has to say about TherapeuticsMD Inc.

    TherapeuticsMD Inc NASDAQ/NGS:TXMDView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is extremely high for TXMD with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TXMD. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding TXMD is favorable, with net inflows of $2.51 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • TherapeuticsMD Enters Agreement to Market Drugs Outside US
    Zacks

    TherapeuticsMD Enters Agreement to Market Drugs Outside US

    TherapeuticsMD (TXMD) grants exclusive commercialization rights to its drugs, Bijuva and Imvexxy, to Theramex in ex-U.S. markets except for Canada and Israel.

  • Business Wire

    TherapeuticsMD to Host Investor and Analyst Day Today

    TherapeuticsMD, Inc. (TXMD), an innovative, leading women’s healthcare company, will host its Investor and Analyst Day today in New York City. Members of TherapeuticsMD’s management team and key opinion leaders will provide updates on the company’s commercial programs and TherapeuticsMD’s management team will provide financial guidance for 2019. A live webcast and audio archive for the event may be accessed on the home page or from the “Investors & Media” section of the TherapeuticsMD website at www.therapeuticsmd.com.

  • Business Wire

    TherapeuticsMD and Theramex Enter into Exclusive License and Supply Agreement to Commercialize BIJUVA™ and IMVEXXY® Outside the United States

    TherapeuticsMD, Inc. (TXMD), an innovative, leading women’s healthcare company, today announced that it has entered into an exclusive license and supply agreement with Theramex, a leading, global specialty pharmaceutical company dedicated to women’s health, to commercialize BIJUVA (estradiol and progesterone capsules) and IMVEXXY (estradiol vaginal inserts) outside of the United States. Theramex is a portfolio company of CVC Capital Partners.

  • Business Wire

    TherapeuticsMD to Host Investor and Analyst Day on June 10, 2019 in New York City

    TherapeuticsMD, Inc. (TXMD), an innovative, leading women’s healthcare company, today announced that it will host an Investor and Analyst Day on Monday, June 10, 2019, in New York City. Members of TherapeuticsMD’s management team and key opinion leaders will provide updates on the company’s commercial programs.

  • Business Wire

    TherapeuticsMD Announces Participation at the Bank of America Merrill Lynch 2019 Health Care Conference

    TherapeuticsMD, Inc. (TXMD), an innovative, leading women’s healthcare company, today announced that the company will participate in the Bank of America Merrill Lynch 2019 Health Care Conference. Chief Executive Officer Robert G. Finizio will provide an overview of the company at the conference.

  • Here's Why TherapeuticsMD Fell as Much as 17.6% Today
    Motley Fool

    Here's Why TherapeuticsMD Fell as Much as 17.6% Today

    The women's health company reported first-quarter 2019 operating results.

  • TherapeuticsMD Inc (TXMD) Q1 2019 Earnings Call Transcript
    Motley Fool

    TherapeuticsMD Inc (TXMD) Q1 2019 Earnings Call Transcript

    TXMD earnings call for the period ending March 31, 2019.